Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Regulation of Pharmacogene Expression by microRNA in The Cancer Genome Atlas (TCGA) Research Network

  • Han, Nayoung (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Song, Yun-Kyoung (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Burckart, Gilbert J. (Office of Clinical Pharmacology, Office of Translational Sciences, Food and Drug Administration) ;
  • Ji, Eunhee (College of Pharmacy, Gacheon University) ;
  • Kim, In-Wha (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Oh, Jung Mi (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University)
  • Received : 2017.06.11
  • Accepted : 2017.06.26
  • Published : 2017.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Individual differences in drug responses are associated with genetic and epigenetic variability of pharmacogene expression. We aimed to identify the relevant miRNAs which regulate pharmacogenes associated with drug responses. The miRNA and mRNA expression profiles derived from data for normal and solid tumor tissues in The Cancer Genome Atlas (TCGA) Research Network. Predicted miRNAs targeted to pharmacogenes were identified using publicly available databases. A total of 95 pharmacogenes were selected from cholangiocarcinoma and colon adenocarcinoma, as well as kidney renal clear cell, liver hepatocellular, and lung squamous cell carcinomas. Through the integration analyses of miRNA and mRNA, 35 miRNAs were found to negatively correlate with mRNA expression levels of 16 pharmacogenes in normal bile duct, liver, colon, and lung tissues (p<0.05). Additionally, 36 miRNAs were related to differential expression of 32 pharmacogene mRNAs in those normal and tumorigenic tissues (p<0.05). These results indicate that changes in expression levels of miRNAs targeted to pharmacogenes in normal and tumor tissues may play a role in determining individual variations in drug response.

Keywords

References

  1. Agarwal, V., Bell, G. W., Nam, J. W. and Bartel, D. P. (2015) Predicting effective microRNA target sites in mammalian mRNAs. Elife 4, e05005.
  2. Bahar, A. Y., Sayar, H., Ulasli, M., Bayraktar, R., Kirkbes, S., Sercan Simsek, S. and Arslan, A. (2017) Expression of miR-520-d-3p, miR-520b, miR-520e are significantly downregulated in locally advanced colorectal carcinoma. Tenn. Med. 2, 11.
  3. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B. 57, 289-300.
  4. Betel, D., Wilson, M., Gabow, A., Marks, D. S. and Sander, C. (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res. 36, D149-D153.
  5. Chen, D. T., Hernandez, J. M., Shibata, D., McCarthy, S. M., Humphries, L. A., Clark, W., Elahi, A., Gruidl, M., Coppola, D. and Yeatman, T. (2012) Complementary strand microRNAs mediate acquisition of metastatic potential in colonic adenocarcinoma. J. Gastrointest. Surg. 16, 905-912; discussion 912-903. https://doi.org/10.1007/s11605-011-1815-0
  6. Chen, Y., Song, Y., Wang, Z., Yue, Z., Xu, H., Xing, C. and Liu, Z. (2010) Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J. Gastrointest. Surg. 14, 1170-1179. https://doi.org/10.1007/s11605-010-1202-2
  7. Dai, Y. and Zhou, X. (2010) Computational methods for the identification of microRNA targets. Open Access Bioinformatics 2, 29-39.
  8. Djuranovic, S., Nahvi, A. and Green, R. (2012) miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science 336, 237-240. https://doi.org/10.1126/science.1215691
  9. Dluzen, D. F. and Lazarus, P. (2015) MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors. Drug Metab. Rev. 47, 320-334.
  10. Georgitsi, M., Zukic, B., Pavlovic, S. and Patrinos, G. P. (2011) Transcriptional regulation and pharmacogenomics. Pharmacogenomics 12, 655-673. https://doi.org/10.2217/pgs.10.215
  11. Hsu, S. D., Chu, C. H., Tsou, A. P., Chen, S. J., Chen, H. C., Hsu, P. W., Huang, H. D. (2008) miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res. 36, D165-D169.
  12. Huang, J., Gutierrez, F., Strachan, H. J., Dou, D., Huang, W., Smith, B., Blake, J. A., Eilbeck, K., Natale, D. A., Lin, Y., Wu, B., de Silva, N., Wang, X., Liu, Z., Borchert, G. M., Tan, M. and Ruttenberg, A. (2016) OmniSearch: a semantic search system based on the Ontology for MIcroRNA Target (OMIT) for microRNA-target gene interaction data. J. Biomed. Semantics. 7, 25. https://doi.org/10.1186/s13326-016-0064-2
  13. Huang, R. S., Gamazon, E. R., Ziliak, D., Wen, Y., Im, H. K., Zhang, W., Wing, C., Duan, S., Bleibel, W. K., Cox, N. J. and Dolan, M. E. (2011) Population differences in microRNA expression and biological implications. RNA Biol. 8, 692-701. https://doi.org/10.4161/rna.8.4.16029
  14. Kim, I. W., Han, N., Burckart, G. J. and Oh, J. M. (2014) Epigenetic changes in gene expression for drug-metabolizing enzymes and transporters. Pharmacotherapy 34, 140-150. https://doi.org/10.1002/phar.1362
  15. Klein, T. E., Chang, J. T., Cho, M. K., Easton, K. L., Fergerson, R., Hewett, M., Lin, Z., Liu, Y., Liu, S., Oliver, D. E., Rubin, D. L., Shafa, F., Stuart, J. M. and Altman, R. B. (2001) Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J. 1, 167-170. https://doi.org/10.1038/sj.tpj.6500035
  16. Koturbash, I., Tolleson, W. H., Guo, L., Yu, D., Chen, S., Hong, H., Mattes, W. and Ning, B. (2015) microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment. Biomark. Med. 9, 1153-1176. https://doi.org/10.2217/bmm.15.89
  17. Kwekel, J. C., Vijay, V., Desai, V. G., Moland, C. L. and Fuscoe, J. C. (2015) Age and sex differences in kidney microRNA expression during the life span of F344 rats. Biol. Sex Differ. 6, 1. https://doi.org/10.1186/s13293-014-0019-1
  18. Messingerova, L., Imrichova, D., Kavcova, H., Seres, M., Sulova, Z. and Breier, A. (2016) A decrease in cellular microRNA-27a content is involved in azacytidine-induced P-glycoprotein expression in SKM-1 cells. Toxicol. In vitro 36, 81-88. https://doi.org/10.1016/j.tiv.2016.07.002
  19. Murakami, Y., Kubo, S., Tamori, A., Itami, S., Kawamura, E., Iwaisako, K., Ikeda, K., Kawada, N., Ochiya, T. and Taguchi, Y. H. (2015) Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Sci. Rep. 5, 16294. https://doi.org/10.1038/srep16294
  20. Nasr, R., Sleiman, F., Awada, Z. and Zgheib, N. K. (2016) The pharmacoepigenetics of drug metabolism and transport in breast cancer: review of the literature and in silico analysis. Pharmacogenomics 17, 1573-1585. https://doi.org/10.2217/pgs-2016-0081
  21. Paraskevopoulou, M. D., Georgakilas, G., Kostoulas, N., Vlachos, I. S., Vergoulis, T., Reczko, M., Filippidis, C., Dalamagas, T. and Hatzigeorgiou, A. G. (2013) DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 41, W169-W173. https://doi.org/10.1093/nar/gkt393
  22. Pasquinelli, A. E. (2012) MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat. Rev. Genet. 13, 271-282. https://doi.org/10.1038/nrg3162
  23. Relling, M. V. and Evans, W. E. (2015) Pharmacogenomics in the clinic. Nature 526, 343-350. https://doi.org/10.1038/nature15817
  24. Rieger, J. K., Klein, K., Winter, S. and Zanger, U. M. (2013) Expression variability of absorption, distribution, metabolism, excretionrelated microRNAs in human liver: influence of nongenetic factors and association with gene expression. Drug Metab. Dispos. 41, 1752-1762. https://doi.org/10.1124/dmd.113.052126
  25. Rukov, J. L. and Shomron, N. (2011) MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. Trends Mol. Med. 17, 412-423. https://doi.org/10.1016/j.molmed.2011.04.003
  26. Sayed, D. and Abdellatif, M. (2011) MicroRNAs in development and disease. Physiol. Rev. 91, 827-887. https://doi.org/10.1152/physrev.00006.2010
  27. Shomron, N. (2010) MicroRNAs and pharmacogenomics. Pharmacogenomics 11, 629-632. https://doi.org/10.2217/pgs.10.26
  28. Vejnar, C. E. and Zdobnov, E. M. (2012) MiRmap: comprehensive prediction of microRNA target repression strength. Nucleic Acids Res. 40, 11673-11683. https://doi.org/10.1093/nar/gks901
  29. Wang, W. C., Juan, A. H., Panebra, A. and Liggett, S. B. (2011) MicroRNA let-7 establishes expression of ${\beta}2$-adrenergic receptors and dynamically down-regulates agonist-promoted down-regulation. Proc. Natl. Acad. Sci. U.S.A. 108, 6246-6251. https://doi.org/10.1073/pnas.1101439108
  30. Wei, Z., Jiang, S., Zhang, Y., Wang, X., Peng, X., Meng, C., Liu, Y., Wang, H., Guo, L., Qin, S., He, L., Shao, F., Zhang, L. and Xing, Q. (2014) The effect of microRNAs in the regulation of human CYP3A4: a systematic study using a mathematical model. Sci. Rep. 4, 4283.
  31. Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C. and Stuart, J. M. (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113-1120. https://doi.org/10.1038/ng.2764
  32. Wienholds, E., Kloosterman, W. P., Miska, E., Alvarez-Saavedra, E., Berezikov, E., de Bruijn, E., Horvitz, H. R., Kauppinen, S. and Plasterk, R. H. (2005) MicroRNA expression in zebrafish embryonic development. Science 309, 310-311. https://doi.org/10.1126/science.1114519
  33. Wilczynska, A. and Bushell, M. (2015) The complexity of miRNA-mediated repression. Cell Death Differ. 22, 22-33. https://doi.org/10.1038/cdd.2014.112
  34. Wong, N. and Wang, X. (2015) miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43, D146-D152. https://doi.org/10.1093/nar/gku1104
  35. World Health Organization (2014) International Agency for Research on Cancer. World Cancer Report.
  36. Yang, C., Sun, C., Liang, X., Xie, S., Huang, J. and Li, D. (2016) Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer. Cancer Gene Ther. 23, 90-97. https://doi.org/10.1038/cgt.2016.5
  37. Ye, B., Wang, R. and Wang, J. (2016) Correlation analysis of the mRNA and miRNA expression profiles in the nascent synthetic allotetraploid Raphanobrassica. Sci. Rep. 6, 37416. https://doi.org/10.1038/srep37416
  38. Yu, A. M., Tian, Y., Tu, M. J., Ho, P. Y. and Jilek, J. L. (2016) MicroRNA pharmacoepigenetics: posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy. Drug Metab. Dispos. 44, 308-319. https://doi.org/10.1124/dmd.115.067470
  39. Yu, A. M. and Pan, Y. Z. (2012) Noncoding microRNAs: Small RNAs play a big role in regulation of ADME? Acta Pharm. Sin. B 2, 93-101. https://doi.org/10.1016/j.apsb.2012.02.011
  40. Zheng, N., Yang, P., Wang, Z. and Zhou, Q. (2017) OncomicroRNAsmediated tumorigenesis: implication in cancer diagnosis and targeted therapy. Curr. Cancer Drug Targets 17, 40-47.